ARCHIVES

As patients worry about COX-2 inhibitors, scientists and FDA review toxicity data.

This article is from The Cancer Letter archive.

Vol. 30 No. 40 | October 22, 2004

Download PDF Visit The Full Archive

Related Articles

In Brief: Million, Donaldson Head ASTRO; James Weese Moves To Presbyterian; Ginder Replaces Kennedy

November 9, 1990

Obama Executive Order Gives FDA Authority To Combat Drug Shortages

November 4, 2011

FDA’s Commitment To Cancer No Different Than Other Diseases, Kessler Tells Advocate

August 14, 1992

DCBDC Board OK’s Concepts For New Small Grant Programs

March 23, 1990

In Brief: FDA Names DeLap Directory Of Oncology

June 7, 1996

Tykerb And Trastuzumab Showed Increase In PFS For HER2+ Breast Cancer In Study

May 30, 2008